SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 4:10 PM ET
SAB Biotherapeutics Inc (SABS) Stock Chart
SAB Biotherapeutics (SABS) has a latest price of $2.95 on Nov 17, 2026, 42.7% below its 52-week high of $5.15. Its price fell 9.0% over the past 12 months. The month-end price fell 95.8% over the 5 years through Oct 2026, a compound annual decline of 46.9%.
Price Chart
From Feb 2021 to Oct 2026, its highest month-end close was $108.90 in Nov 2021 and its lowest $1.36 in Mar 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart SABS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for SABS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 22.0%, and over 6 months it fell 16.9%. The month-end price fell 66.5% over the 3 years through Oct 2026, a compound annual decline of 30.5%.
| Period | Change |
|---|---|
| 1 month | +13.5% |
| 3 months | -22.0% |
| 6 months | -16.9% |
| 12 months | -9.0% |
| 12 months, with dividends | -9.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -66.5% | -30.5% |
| 5 years | -95.8% | -46.9% |
Price by Year
Its best calendar year was 2023, when the price rose 16.5%, and its weakest was 2022, when it fell 92.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.35 | -10.4% |
| 2025 | $3.74 | -1.4% |
| 2024 | $3.79 | -44.8% |
| 2023 | $6.88 | +16.5% |
| 2022 | $5.90 | -92.4% |
Trading Range
The price is 4.7% below its 50-day average of $3.09 and 18.4% below its 200-day average of $3.61.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.95 | |
| 52-week high | $5.15 | -42.7% |
| 52-week low | $2.44 | +20.9% |
| 50-day average | $3.09 | -4.7% |
| 200-day average | $3.61 | -18.4% |
Price Risk
Over 3 years, its largest fall from a peak was 88.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.07 |
| Largest fall, 1 year | -45.8% |
| Largest fall, 3 years | -88.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About SABS
What is SABS's 1-year price change?
SAB Biotherapeutics's price fell 9.0% over the past 12 months. With dividends included, the 12-month total return was -9.0%.
What is SABS's 5-year price change?
SAB Biotherapeutics's month-end price fell 95.8% over the 5 years through Oct 2026, a compound annual decline of 46.9%. These figures leave out dividends.
What is SABS's 52-week high and low?
SAB Biotherapeutics's 52-week high is $5.15 and its 52-week low is $2.44. Its latest price of $2.95 on Nov 17, 2026 is 42.7% below the high.
What is SABS's beta?
SAB Biotherapeutics's 1-year beta against the S&P 500 is 1.07, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 45.8%.
Is the SABS chart free?
Yes. Advanced Charting for SABS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
SABS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors